Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Meta Expands AI Training With Employee Activity Tracking Tools 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
NEWARK, Calif., March 16, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that it will host a conference call and live audio webcast on Thursday, March 23 at 4:30 p.m. Eastern Time to discuss fourth quarter and full year 2016 financial results and provide a business update.
Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13656344. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies to treat specialty and orphan diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional Information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
